SNY » Topics » Pro forma amortization and impairment of intangibles

This excerpt taken from the SNY 20-F filed Apr 11, 2005.

Pro forma amortization and impairment of intangibles

 

Pro forma charges for amortization and impairment of intangibles amounted to €3,950 million in 2004, after the elimination for pro forma purposes of €11 million of amortization relating to Arixtra® and Fraxiparine® and €94 million of amortization of Aventis intangible assets, and after recognition of a charge of €2,398 million for the amortization of the acquired intangible assets of Aventis. Overall, this represents a decrease of 5.3% relative to the 2003 pro forma figure of €4,171 million. The decrease in amortization was mainly due to the effect of exchange rates.

 

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki